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of an HIV infection should be considered.7 However, to date
the authors are unaware of any previous report on perianal
tuberculosis in an HIV-infected individual.
The tuberculin skin test may be negative in patients with
orificial tuberculosis. This phenomenon is called `negative
anergy' and is caused by a decrease in tuberculo-specific host
defence at the time of a severe infection.8 It is important not
to depend solely on a negative result of the tuberculin skin
test. Histopathological examination of an ulcer edge is often
the key to the correct diagnosis.9 Polymerase chain reaction
(PCR) is promising as a future diagnostic technique and can
probably lead to a quicker and more accurate diagnosis, but
cultures should always be done to confirm PCR results and
determine drug resistance.10
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Hepatitis C virus: a common triggering factor for both
nodular vasculitis and SjoÈ gren's syndrome?
Sir, Nodular vasculitis (NV) is a lobular panniculitis
associated with vasculitis of the septal blood vessels. It is
characterized by a chronic eruption of nodular, erythematous
and painful lesions that occur predominantly on the posterior
and lateral surfaces of the legs. These lesions can evolve into
bluish-red plaques. They may ulcerate and, after healing,
leave atrophic scars.1 Infections are one of the most
important causes of NV.
SjoÈgren's syndrome (SS) is characterized by dry eyes
(xerophthalmia) and dry mouth (xerostomia),2 resulting
from a lymphocytic infiltrate of the lacrimal and salivary
glands. Hepatitis C virus (HCV)-associated SS has been widely
reported. HCV infection is also often associated with
cutaneous vasculitis, mainly related to cryoglobulinaemia.3
We report the case of a patient with HCV hepatitis who
subsequently developed cutaneous NV and SS.
A 65-year-old Caucasian woman presented with a symme-
trical eruption of erythemato-cyanotic, subcutaneous nodules
of the lower legs and the abdomen. She reported a 10-year
history of painful nodular lesions with a particular preference
for the calf area. These lesions had a chronic recurrent
course, occurring frequently during the winter. Shortly after
the onset of the skin problems, she developed xerophthalmia,
xerostomia, arthralgia, myalgia and recurrent swelling of the
parotid glands. She had a history of chronic HCV infection
diagnosed 14 years previously. Physical examination revealed
several tender, erythemato-cyanotic, oedematous nodules,
0´5±2 cm in size distributed on the lower legs (Fig. 1a) and
abdomen; some of these lesions were ulcerated. Hyperpig-
mented, atrophic scars could be observed also. A biopsy taken
from a nodule of the left leg mainly showed septal panniculitis
with vasculitis (arteritis) (Fig. 1b), and to a lesser extent
lobular panniculitis, with fat cell necrosis and granulomatous
inflammation (Fig. 1c).
Cultures for fungi and atypical mycobacteria were negative.
Neither immunoglobulins nor complement components were
found by direct immunofluorescence (DIF) on lesional skin.
Polymerase chain reaction (PCR) assay on the skin specimen
did not detect HCV RNA. Biopsy of minor salivary glands
revealed lymphocytic sialadenitis (grade 3 according to
Chisholm and Mason scoring system). Routine laboratory
investigations were normal except for a slight increase in
g-glutamyl transpeptidase at 79 U/L (normal 5±40 U/L),
aspartate transaminase at 43 U/L and alanine transferase at
61 U/L (normal 5±40 U/L). No cryoglobulins were detected
on three different occasions. The following studies were either
negative or within normal limits: circulating immune
complexes (determined by ELISA), serum amylase and lipase,
a1-antitrypsin, complement activity, angiotensin-converting
enzyme. Anti-HCV antibodies and serum HCV RNA detection
by PCR confirmed the previously diagnosed HCV infection.
Serologic tests for hepatitis B virus, HIV and Epstein±Barr
virus were negative. Antinuclear antibodies were repeatedly
positive (1 : 20±1 : 160), while anti-ds-DNA was positive
(63´6 iu/mL; negative , 35, borderline 35±55, positive
. 55) on only one occasion. Anti-Ro/SSA and La/SSB
antibodies were negative, as was the tuberculin skin test
reaction. The chest X-ray was normal, and abdominal
ultrasound showed hepatomegaly. Ocular involvement was
confirmed by a positive Schirmer's test.
The liver biopsy showed a lymphohistiocytic infiltrate in
portal tracts, focal hepatocellular necrosis and diffuse fibrosis.
The diagnosis of SS was made according to the criteria
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recently established by the European Community Study
Group.4 The diagnosis of nodular vasculitis was established
on the basis of the clinical features and histological analysis.
The patient did not respond to systemic corticosteroid
treatment, while good results were obtained with dapsone
(75 mg/daily), although discontinuation of the treatment was
followed by relapse.
The relationship between HCV and SS is not yet fully clear,
but a possible role for HCV in the pathogenesis of SS has been
hypothesized.5,6 Indeed, some authors state that HCV may be
involved in the pathogenesis of a pseudo-SS, in which the
clinical and pathological features resemble those of SS, but
anti-SSA and anti-SSB antibodies are negative.5,6
The most likely pathogenic hypothesis for the association of
HCV, NV and SS is the triggering of immune-mediated
mechanisms by HCV. The local deposition of circulating
immune complexes (antibodies against HCV antigens?) might
be the initial pathogenic mechanism involved in NV.7
Subsequently, a delayed-type hypersensitivity might be
important in determining the chronic course of the disease.7
An interesting, additional point is the good response of
both HCV hepatitis and cutaneous vasculitis to interferon-a
treatment. In fact, interferon resulted in a clear-cut
improvement of the cutaneous lesions in a case of HCV-
related cryoglobulinaemia with manifestations of cutaneous
vasculitis.3 Durand and coworkers8 provide strong additional
evidence for the role of HCV as aetiological agent in
cutaneous vasculitis: HCV RNA was detected in lesional
skin by PCR, and again interferon was found to be effective in
resolving skin lesions.
We propose that HCV might be the cause of both SS and NV
in our patient, as the clinical manifestations became evident
only after the patient had contracted the HCV infection.
Moreover, no other known cause of NV was revealed in our
investigations.
C.CARD INAL I
G.GER LIN I
M.CAPRON I
N.PIMPINELLI
P.FABBR I
Clinica Dermatologica II,
UniversitaÁ degli Studi di Firenze,
Via della Pergola 58,
50121,Firenze, Italy
E-mail: fabbri@cesit1.unifi.it
References
1 Bondi EE, Lazarus GS. Disorders of subcutaneous tissue. In:
Dermatology in General Medicine (Fitzpatrick TB, Eisen AZ, Wolff K,
Freedberg IM, Austen KF, eds), 4th edn, Vol. 1. New York: McGraw-
Hill, 1993: 1337±8.
2 Fox RI. Epidemiology, pathogenesis, animal models, and treatment
of SjoÈgren's syndrome. Curr Opin Rheumatol 1994; 6: 501±8.
Figure 1. (a) Clinical aspect: erythemato-cyanotic, subcutaneous
nodule of the lower leg with central ulceration. (b) Skin biopsy
showing infiltration of vessel walls by mononuclear cells associated
with endothelial cell swelling (haematoxylin and eosin, original
magnification 250). (c) Skin biopsy showing granulomatous
inflammatory infiltrate in the fat lobules and in the septa composed
of lymphoid cells, histiocytes, epithelioid cells (haematoxylin and
eosin, original magnification 200).
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Radiotherapy and erythema nodosum
Sir, We were interested to read a recent article of corre-
spondence published in the journal by Takagawa et al. about
radiation induced erythema nodosum.1 Despite few reports in
the literature we believe that it is not an uncommon
association and relatively commonly encountered. We report
another patient who developed erythema nodosum after
radiation therapy for a uterine leiomyosarcoma.
A 49-year-old woman was diagnosed as having a high-
grade uterine leiomyosarcoma in 1998 after a hysterectomy
was performed for irregular menstrual bleeding and rapidly
enlarging fibroids. She was subsequently treated with
external beam radiotherapy to the pelvis to a total dose of
45 Gy in 25 fractions over 5 weeks. Intracavity brachy-
therapy to a total dose of 8 Gy was also administered on
two separate occasions. Ten days after starting radiotherapy
(11 fractions) the patient noticed a firm painful erythematous
lesion on the back of the right calf. Over the next few weeks
while continuing radiotherapy similar lesions erupted over
the left calf and right shin. She was referred to the
dermatology department and a clinical diagnosis of erythema
nodosum was made.
This was confirmed by a skin biopsy which showed a septal
and lobular panniculitis. Ziehl±Neelsen stain for acid-fast
bacilli was negative and there was no growth from skin sent
for culture. Investigations including a full blood count,
calcium, amylase, serum angiotensin-converting enzyme
inhibitor, a1-antitrypsin level and antistreptolysin titre were
either normal or negative. Liver function tests revealed an
elevated g-glutamyl transpeptidase of 51 U/L (normal: , 35).
The erythrocyte sedimentation rate over 1 h was slightly
raised at 27 mm/h (normal: , 20). The chest X-ray was
unremarkable. Mantoux test with tuberculin 1 in 10,000 was
within normal limits.
She was treated with oral erythromycin, topical clobetasol
propionate and systemic non-steroidal anti-inflammatory
drugs. No further radiotherapy has been administered and
the lesions completely resolved within 8 weeks.
Erythema nodosum is a reactive dermatosis with an
unknown pathogenesis. In some patients with erythema
nodosum an underlying disease such as streptococcal
infection, sarcoid or tuberculosis is identified; however, in
approximately one-half of the cases no causative factor can
be found.2 It is possible that radiation treatment has not
been considered as a causative factor or that the associ-
ation is not well recognized and for either reason therefore
under-reported.
Another reactive dermatosis, Sweet's syndrome, has also
been associated with radiotherapy.3 This and erythema
nodosum can occur simultaneously and may share a
common mechanism of pathogenesis.4 Takagawa et al.
speculate that in patients with radiation-induced erythema
nodosum, breakdown products of cancer cells destroyed by
radiation might activate circulating antibodies and comple-
ment to form immune complexes thereby triggering the
reaction. Erythema nodosum did not recur after the further
sessions of radiotherapy and they proposed that this was
because there was not enough residual tumour left to release
breakdown products. The tumour in our patient had been
surgically removed prior to radiotherapy and the onset of the
erythema nodosum. Whatever the mechanism it seems
certain that radiotherapy can act to trigger several reactive
dermatoses.
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Interferon alpha 2b for treatment of complex
cutaneous haemangiomas of infancy: a reduced
dosage schedule
Sir, the treatment of complex infantile haemangiomas (IHs)
with subcutaneous interferon (IFN) a2b or 2a is usually
performed with doses as high as 2±3 million U/m2 per day for
many months.1 We have previously reported on the efficacy
of lower doses.2 The efficacy of even lower IFN doses is
described here.
Eight patients, six females and two males with complex
cutaneous haemangiomas were studied. At the onset of
treatment, their ages ranged from 2 to 11 months. Five
